Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 11/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 5/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7727313 | 0.84 | BTK (0.46) | BTKMMP2ANPEPCTSKHSD11B1 | |
| SCHEMBL7731684 | 0.84 | BTK (0.46) | BTKMMP2ANPEPCTSKHSD11B1 | |
| SCHEMBL7727315 | 0.84 | BTK (0.46) | BTKMMP2ANPEPCTSKHSD11B1 | |
| SCHEMBL22506037 | 0.80 | BTK (0.49) | BTKMMP2ANPEPCTSKHSD11B1 | |
| SCHEMBL27100711 | 0.80 | MMP2 (0.56) | BTKMMP2ANPEPCTSKHSD11B1 | |
| SCHEMBL22980156 | 0.79 | MMP2 (0.47) | MMP2ANPEPCTSKHSD11B1CYP2C9 | |
| SCHEMBL21520375 | 0.79 | MMP2 (0.49) | MMP2ANPEPKMT2AL3MBTL1 | |
| SCHEMBL12164621 | 0.79 | MMP2 (0.49) | MMP2ANPEPKMT2AL3MBTL1 | |
| SCHEMBL21520377 | 0.79 | MMP2 (0.49) | MMP2ANPEPKMT2AL3MBTL1 | |
| SCHEMBL8830957 | 0.79 | MMP2 (0.49) | MMP2ANPEPKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469609-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2016-10-18 | — | — | US | disclosed |
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2015-11-12 | — | — | US | disclosed |
| US-8927590-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| US-20130053344-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| EP-2468724-A1 | Synthesis of pyrrolidine compounds | Zealand Pharma A/S (DK) | 2012-06-27 | — | — | EP | disclosed |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | WYETH LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | ZEALAND PHARMA A/S (DK) | 2008-08-07 | — | — | US | disclosed |
| WO-2008079266-A2 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | WYETH (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053344-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | BTK 4609/4885MMP2 3894/4885MMP9 4651/4885 |
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | BTK 4609/4885MMP2 3894/4885MMP9 4651/4885 |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | GLS, COL2A1, MYOC | BTK 4649/4885MMP2 970/4885MMP9 986/4885 |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | BTK 4609/4885MMP2 3894/4885MMP9 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.